Best of PCR e-Course 2020

In case you missed, watch recordings of LAA Closure, Mitral, TAVI and Tricuspid late breaking trials and scientific sponsored sessions.

LAA OCCLUSION VS. NOVEL ORAL ANTICOAGULATION IN ATRIAL FIBRILLATION

 

J.E. Nielsen-Kudsk

watch now

HOW DOES THE LATEST TENDYNE TMVI CLINICAL EVIDENCE CHANGE HEART TEAM DECISIONS?
 

D. Muller

watch now

PERCUTANEOUS EDGE-TO-EDGE REPAIR FOR TRICUSPID REGURGITATION: 1-YEAR OUTCOMES FROM TRILUMINATE TRIAL

P. Lurz

watch now

HOTLINE LATE-BREAKING TRIALS

  • LEFT ATRIAL APPENDAGE CLOSURE

    Amulet IDE Roll-in cohort  (S. Windecker)

    LAA occlusion vs. novel oral anticoagulation  (J.E. Nielsen-Kudsk)

    Watch

  • MITRAL INTERVENTIONS - PART 1

    Two-year outcomes of Tendyne TMVI  (D. Muller)

    Feasibility study of Tendyne mitral valve system in mitral annular calcification  (P. Sorajja)

    Watch

  • MITRAL INTERVENTIONS - PART 2: GLOBAL EXPAND REGISTRY

    Safety and effectiveness outcomes with MitraClip XTR system  (M.J. Price )

    Clip selection strategy and outcomes with MitraClip (NTR/XTR)  (F. Maisano)

    Clinical outcomes with MitraClip (NTR/XTR): core-lab echo results (W. Rottbauer)

    Mitral valve leaflet adverse events with MitraClip (F. Asch)

    Watch

  • TAVI Part 2

    Two-year outcomes from the PORTICO IDE trial  (R. Makkar)

    Safety outcomes for the FlexNav DS Global cohort  (F. Bedogni)

    Watch

  • TRICUSPID INTERVENTIONS

    One-year TRILUMINATE trial results (P. Lurz)

    Watch

Scientific Sponsored sessions

  • LAA Closure

    LEFT ATRIAL APPENDAGE OCCLUSION VERSUS NOVEL ORAL ANTICOAGULATION IN ATRIAL FIBRILLATION

    Chair  U. Landmesser        Discussants  S. Windecker, D. Hildick-Smith

    Watch

    Attend this session if you want:

    • To learn about which patients may benefit from LAA occlusion vs. long term anticoagulation
    • To learn about the latest data of LAAO vs. NOACs from a substantial cohort in a propensity score matched study

    Agenda:

    Introduction and session objectives  (U. Landmesser)

    Moderated discussion  (S. Windecker, D. Hildick-Smith)

    • Unmet need: Alternative to medical therapy (long-term NOAC therapy)
    • What does the latest data tell us: Results from a propensity score matched follow-up study based on the Amulet Observational registry
    • Immediate impact: LAA occlusion viable alternative to OAC including NOACs, this to be confirmed in future trials
    • Outlook: Catalyst trial evaluating safety and effectiveness of Amulet compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and systemic embolism, and who are recommended for long-term NOAC therapy

    Key Learnings  (U. Landmesser)

  • MITRAL

    TAILORING MITRAL VALVE REPAIR TO IMPROVE PATIENT OUTCOMES: CONTEMPORARY EVIDENCE

    Chair  F. Maisano            Discussants S. Kar, M. Sitges

    Watch

    Attend this session if you want:

    • To tailor the mitral valve repair and optimize treatment based on etiology and mitral valve anatomy
    • To learn about current MitraClip clip options as well as look in the future of the mitral repair treatment

    Agenda:

    Session objectives
    F. Maisano

    Learnings from Largest Contemporary Real-World, All Comer Mitral Repair Outcomes
    Dr. Kar

    Tailoring Mitral Valve Repair: Evidence based recommendation for Clip selection
    F. Maisano

    Importance of appropriate mitral valve leaflet visualization for outcomes
    M. Sitges

    What does the mitral valve repair future hold?
    S. Kar

    Session Learnings
    F. Maisano

  • MITRAL

    NEW TMVI THERAPY TO ELIMINATE MITRAL REGURGITATION. EVIDENCE & PATIENT SELECTION

    Chair N. Dumonteil           Discussants  A. Duncan, L. Conradi

    Watch

    Attend this session if you want:

    • To learn about the latest update on Tendyne TMVI clinical experience
    • To learn about which patients may benefit from this novel therapeutical option

    Agenda:

    Introduction and session objectives  (N. Dumonteil)

    What is Tendyne TMVI and current clinical experience  (N. Dumonteil)

    • Echo screening (A. Duncan)
    • CT screening (L. Conradi)
    • First commercial cases overview (L. Conradi)

    Discussion and key learnings  (N. Dumonteil)

  • TAVI

    PORTICO FLEXNAV: OPTIMIZE TAVI OUTCOMES FROM ROUTINE TO COMPLEX CASES - LIVE IN A BOX

    Chair  L. Sondergaard     Discussants  H. Möllmann, M. Mullen

    Watch

    Attend this session if you want:

    • To learn more about the new Portico with FlexNav TAVI system and its industry leading deliverability
    • To learn how Portico enables you to achieve excellent hemodynamics and patient outcomes
    • To learn importance of “looking ahead” during TAVI and ensuring patients coronary access preservation

    Agenda:

    Session objectives  (L. Sondergaard)

    Portico with FlexNav latest clinical evidence & procedural benefits  (H. Möllmann)

    Innovation at its best, new Portico with FlexNav TAVI System  (M. Mullen)

    Portico with FlexNav Procedural Highlights  (L. Sondergaard)

    Session Learnings  (L. Sondergaard)

  • TRICUSPID

    CLIP TECHNOLOGY YOU KNOW AND TRUST, DESIGNED FOR THE TRICUSPID VALVE - LIVE IN A BOX

    Chair  G. Nickenig            Discussants  S. von Bardeleben, F. Praz

    Watch

    Attend this session if you want:

    • To learn why diagnosis and treatment of tricuspid regurgitation is the next transcatheter valvular treatment frontier
    • To learn more about TriClip, novel therapy option for patients suffering from TR
    • To learn about patient selection and ensure procedural success

    Agenda:

    Session objectives  (G. Nickenig)

    Tricuspid Regurgitation, disease burden and necessity for treatment  (F. Praz)

    TriClip dedicated treatment option for patients with Tricuspid Regurgitation  (G. Nickenig)

    Overview of the TriClip procedure  (S. von Bardeleben)

    Key Learnings  (G. Nickenig)

Sign Up

Register to stay updated on latest news about Mitral Regurgitation , Aortic Stenosis, Heart Failure management and Stroke Prevention

Register now

Unless otherwise specified, all product and service names appearing herein are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name or trade dress may be made without their prior written authorization of Abbott. Products intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use provided inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. All drawings are artist's representations only and should not be considered as engineering drawings or photographs. Photo(s) on file at Abbott. Information contained herein is for distribution for Europe, Middle East and Africa ONLY. Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

Abbott International BVBA, Park Lane, Culliganlaan 2b, 1831 Diegem, Belgium, tel: +32 2 714 14 11
© 2020 Abbott. All rights reserved. 9-EH-5-11308-01 07-2020 REV A.

You are about to leave AdvancedHeartTherapies.com

You are now leaving AdvancedHeartTherapies.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.